Demeetra AgBio
Demeetra AgBio is a privately held Lexington, KY-based gene editing company that licenses its Cas-CLOVER technology, CleanCut CHO cell line platforms, and transposase systems to biopharma companies, CDMOs, and research institutions for biologics manufacturing and discovery.
- Company typePrivate
- Founded2019
- HeadquartersLexington, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Demeetra AgBio does
Demeetra AgBio is a privately held biotechnology company headquartered in Lexington, Kentucky, that develops and licenses gene editing technologies for biopharmaceutical cell line development, industrial biotechnology, and agricultural applications. The company's core technology is Cas-CLOVER, a dimeric nuclease combining deactivated Cas9 with Clo051 nuclease domains that delivers high-precision editing with sub-1% off-target indel rates, larger deletion capability (8-50+ bp) versus CRISPR/Cas9, and knock-in efficiency up to 20 kb. Cas-CLOVER powers the proprietary CleanCut CHO platform family, including CleanCut GS CHO (double glutamine synthetase knockout for stringent selection and 5+ g/L titers) and CleanCut GS ADCC+ (FUT8 knockout enabling 85-89% afucosylation and 2.0-4.8x ADCC potency improvement). Supporting technologies include the Harbor-IN transposase for license-free stable cell line development and the Super piggyBac transposase acquired via the 2026 Hera BioLabs acquisition.
Demeetra monetizes through three primary streams: technology licensing for Cas-CLOVER, Super piggyBac, and the CleanCut CHO platforms; full-service cell line development coordinated with NorthX Biologics for GMP manufacturing; and platform access products including CleanCut GS ADCC+ sold via one-time GMP implementation fees with unlimited product use and no per-program royalties. The go-to-market is enterprise sales-led with scheduled expert calls, supported by peer-reviewed publications, webinars, and thought leadership content. Customer segments span large biopharmaceutical companies (Sanofi, Takeda, Elanco, Eisai), clinical-stage biotech (Poseida), vaccines (VBI Vaccines), CDMOs (AGC Biologics), and research institutions (Indiana University, IITA). Pricing is quote-based and not publicly disclosed, structured as multi-year contracts.
The company operates with a lean team of 1-10 employees and has no disclosed venture funding. The June 2025 (reportedly completed January 2026) acquisition of Hera BioLabs consolidated exclusive Super piggyBac licensing rights and added in vitro R&D capability, while the NorthX Biologics partnership (announced February 2026) created an integrated gene-to-GMP service offering. Strategic priorities appear centered on expanding enterprise licensing, scaling the CleanCut CHO platform into clinical manufacturing, and extending the platform into adjacent verticals including cell therapy research, animal health, and agriculture.
Demeetra AgBio firmographics
Firmographics- Name
- Demeetra AgBio
- Legal name
- Demeetra AgBio, Inc.
- Website
- https://demeetra.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Demeetra AgBio is a privately held Lexington, KY-based gene editing company that licenses its Cas-CLOVER technology, CleanCut CHO cell line platforms, and transposase systems to biopharma companies, CDMOs, and research institutions for biologics manufacturing and discovery.
- Ownership category
- akta.pro rank
Demeetra AgBio industry classification
Industry- Product category
- Biologics Cell Line Development Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
- akta.pro secondary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Demeetra AgBio is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Demeetra AgBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Technology Licensing: Demeetra licenses its gene editing technologies (Cas-CLOVER, CleanCut CHO platforms, Super piggyBac) to biopharma companies, CDMOs, and research institutions. Licensing provides commercial rights for using the technology in product development and manufacturing.
- Cell Line Development Services: Integrated CLD services generating stable, high-titer cell lines using CleanCut CHO platforms. Services include cell line development and coordination with GMP manufacturing through NorthX Biologics partnership.
- Platform Access Products: CleanCut GS ADCC+ available through one-time GMP implementation fee for unlimited product use, with no per-program royalties or milestone-based access restrictions. Cell lines and reagents sold directly.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | CleanCut GS ADCC+ Platform Access - one-time GMP implementation fee with unlimited product use |
| Other | Multi-year contract | CLD Services - full-service cell line development with GMP manufacturing coordination |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Demeetra AgBio product offering
Product offeringCore offering
Demeetra AgBio develops, licenses, and supplies precision gene editing technologies—led by its proprietary Cas-CLOVER dimeric nuclease system—and production-ready CHO cell line platforms (CleanCut GS CHO, CleanCut GS ADCC+) built on those tools. The company sells licenses and platform access to biopharmaceutical companies, CDMOs, and research institutions, and provides integrated cell line development services coordinated with GMP manufacturing through its NorthX Biologics partnership.
Product overview
Demeetra AgBio offers an integrated platform of gene editing technologies and CHO cell line development products for biopharmaceutical manufacturing. The core offering centers on Cas-CLOVER, a high-fidelity dimeric gene editing system, which powers the CleanCut CHO platform family (including CleanCut GS CHO and CleanCut GS ADCC+ variants) for production-ready cell lines. Supporting technologies include Harbor-IN transposase for stable integration and Super piggyBac for high-capacity gene insertion. The platform is complemented by integrated cell line development services with coordinated GMP manufacturing partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- CleanCut CHO Platform: Suspension CHO-K1 cells precisely engineered with Cas-CLOVER, optimized for high-performance bioprocessing and stable expression.
- Cas-CLOVER
- Harbor-IN Transposase
- Super piggyBac
- CleanCut GS CHO
- CleanCut GS ADCC+
Products and services
- Cas-CLOVER
Quantifiable outcome
- Up to 14.4-fold increase in monoclonal antibody titers using Cas-CLOVER gene editing
- +4 more outcomes
Companies that use Demeetra AgBio
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles4 records
Demeetra AgBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Demeetra AgBio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- NorthX BiologicscoreStrategic partnership integrating Demeetra's CleanCut CHO cell line platforms with NorthX Biologics' GMP manufacturing capabilities to offer end-to-end solutions for biotech companies developing biologics. Collaboration aims to eliminate technical setbacks, remove need for cell line rebuilds, and reduce regulatory risks during transition from early-stage development to clinical material production. Both companies target early-stage biotech companies seeking to accelerate IND-enabling and Phase I milestones.
- Hera BioLabscoreDemeetra completed acquisition of Hera BioLabs on June 1, securing expanded rights to hyperactive Super piggyBac transposase platform. Transaction positions Demeetra as definitive commercial source for licensing across drug discovery, research tools, and commercial applications. Hera's in vitro services incorporated into Demeetra's R&D to accelerate CleanCut CHO Platform development; in vivo services wound down.
- NorthX BiologicscoreJoint webinar collaboration featuring Magnus Gustafsson (CCO of NorthX Biologics) and Jack Crawford (CEO of Demeetra) discussing key early decisions in biologics development and CLD-to-GMP pathway optimization.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Demeetra AgBio competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Lonza is a global CDMO leader offering mammalian cell line development, GMP manufacturing, and integrated biologics services, directly competing with Demeetra/NorthX in the CLD-to-GMP offering space.
- Bio-Techne: Bio-Techne provides reagents, proteins, and cell/gene therapy workflow tools used by biopharma developers, an adjacent supplier with overlapping customer base in cell line engineering and biologics manufacturing.
- Revvity (formerly Horizon Discovery): Revvity's gene editing tools and cell line engineering offerings (via Horizon Discovery) compete in the broader research and cell engineering market with broader portfolio reach and greater resources.
Emerging players
- Caribou Biosciences: Caribou is a clinical-stage gene editing company developing CRISPR-based allogeneic cell therapies, with overlapping gene editing technology focus but different end-market (cell therapy vs CHO bioprocessing).
- Twist Bioscience: Twist provides synthetic biology tools and antibody discovery platforms used by biopharma developers, with overlapping customer base in biologics R&D and complementary offerings in synthetic genes and libraries.
- MaxCyte: MaxCyte provides electroporation-based cell engineering technology widely used in cell therapy and bioprocessing, an adjacent gene editing/cell engineering platform competing for similar biotech customers.
- Cellectis: Cellectis develops gene-edited allogeneic CAR-T therapies using its TALEN platform, offering an alternative gene editing architecture analogous to Cas-CLOVER's positioning versus CRISPR.
Direct peers
- ATUM (formerly DNA2.0): ATUM provides gene synthesis, protein engineering, and CHO cell line development tools and services, directly competing with Demeetra in the CLD platform space for biologics developers.
- GenScript ProBio: GenScript ProBio offers end-to-end cell line development, plasmid/mRNA services, and GMP biologics manufacturing for biopharma, directly overlapping with Demeetra's CLD-to-GMP positioning.
- AGC Biologics: AGC Biologics is both a named Demeetra customer and a competing CDMO providing mammalian cell line development and GMP manufacturing services for biologics developers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Demeetra AgBio social profiles
Digital presenceDemeetra AgBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Demeetra AgBio leadership team
Management profileNumber of profiles
Profiles2 records
Demeetra AgBio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Demeetra AgBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Demeetra AgBio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Demeetra AgBio
What does Demeetra AgBio do?
Demeetra AgBio develops, licenses, and supplies precision gene editing technologies—led by its proprietary Cas-CLOVER dimeric nuclease system—and production-ready CHO cell line platforms (CleanCut GS CHO, CleanCut GS ADCC+) built on those tools. The company sells licenses and platform access to biopharmaceutical companies, CDMOs, and research institutions, and provides integrated cell line development services coordinated with GMP manufacturing through its NorthX Biologics partnership.
Is Demeetra AgBio a public or private company?
Demeetra AgBio is a private company. It is classified as unknown and is currently operating.
When was Demeetra AgBio founded?
Demeetra AgBio was founded in 2019. It employs 1 to 10 people.
Where is Demeetra AgBio based?
Demeetra AgBio is headquartered in Lexington, United States, in the North America region.
How does Demeetra AgBio make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are cell Line Development Services and platform Access Products.
Who are Demeetra AgBio's main competitors?
Broad incumbents on record are Lonza Group, Bio-Techne and Revvity (formerly Horizon Discovery). Emerging players are Caribou Biosciences, Twist Bioscience, MaxCyte and Cellectis. Direct peers are ATUM (formerly DNA2.0), GenScript ProBio and AGC Biologics.
Does Demeetra AgBio have an API?
No public API is recorded for Demeetra AgBio.
What industry is Demeetra AgBio in?
Demeetra AgBio's product category is Biologics Cell Line Development Technology. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 541714 and its SIC code is 2836.